BioNTech Faces Mounting Analyst Skepticism Over Key Drug Trial

Market confidence in BioNTech is being tested as analysts from prominent firms revise their outlooks downward. Leerink Partners has taken a notably more cautious stance, reducing its price target for the company’s shares from $113 to $94. This adjustment reflects growing concerns about the pivotal late-stage trial for one of the firm’s most promising oncology assets.

A Critical Catalyst Under Scrutiny

The primary focus of analyst apprehension is the CTLA-4 antibody candidate, gotistobart. Its success in the ongoing PRESERVE-003 Phase 3 trial is now viewed with increased skepticism. This study is evaluating the drug’s efficacy in patients with metastatic squamous non-small cell lung cancer whose disease has progressed after prior immunotherapy combined with chemotherapy.

Leerink identifies the data readout from this trial as the most significant internal clinical catalyst for BioNTech in the current year. While earlier, non-pivotal phase data had been encouraging—showing clinically meaningful antitumor activity and a 54% reduction in the risk of death compared to standard chemotherapy—recent clinical insights have led the firm to lower its probability-of-success assessment for this crucial phase.

A Multifaceted Challenge

The pressure on BioNTech is not confined to its oncology pipeline. Challenges also persist with its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer. The companies were forced to halt a Phase 3 study required by the U.S. FDA for 2025, which aimed to confirm the booster benefit in healthy adults aged 50 to 64, due to an inability to fully recruit participants. BioNTech attributed the stoppage to a weak COVID-19 season and low case rates, rather than any safety or benefit-risk concerns.

Should investors sell immediately? Or is it worth buying BioNTech?

Further compounding the situation is the announced departure of key leadership. CEO Uğur Şahin and Chief Medical Officer Özlem Türeci are set to step down at year’s end. Although Leerink suggests that strong successors could provide upside potential, it also notes that the share price has already declined by approximately 11% since the announcement. Other financial institutions have also tempered their expectations; BMO Capital and H.C. Wainwright have lowered their price targets to $128 and $130, respectively.

Financial Resilience Amidst Transition

Despite these headwinds, BioNTech retains a substantial financial cushion to support its operations. The company reported a liquidity reserve of approximately €17.2 billion at the end of 2025, which it deems sufficient to fund its ongoing strategic transformation.

However, the financial forecast for 2026 anticipates a significant downturn. Following a net loss of €1.14 billion for the 2025 fiscal year, management projects revenue will fall by roughly 25% to a range of €2.0 to €2.3 billion.

Concurrently, BioNTech is advancing its broader clinical portfolio. The company plans to initiate six additional Phase 3 trials this year and anticipates a total of seven late-stage data readouts. Among these, the outcome of the PRESERVE-003 study for gotistobart remains the single most influential event likely to dictate the stock’s near-term trajectory.